|
注册号: Registration number: |
ChiCTR2600124160 |
|
最近更新日期: Date of Last Refreshed on: |
2026-05-08 10:54:03 |
|
注册时间: Date of Registration: |
2026-05-08 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
妊娠期糖尿病孕妇跨生态位菌群的比较分析 |
|
Public title: |
Comparative Analysis of Cross-Niche Microbiota in Pregnant Women with Gestational Diabetes Mellitus |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
妊娠期糖尿病孕妇跨生态位菌群的比较分析:微生物特征、功能差异及网络互作研究 |
|
Scientific title: |
Comparative Analysis of Cross-Niche Microbiota in Pregnant Women with Gestational Diabetes Mellitus: Microbial Characteristics, Functional Divergence, and Network Interactions |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
高岩 |
研究负责人: |
高岩 |
|
Applicant: |
Gao Yan |
Study leader: |
Gao Yan |
|
申请注册联系人电话: Applicant telephone: |
+86 28 6587 8587 |
研究负责人电话:
Study leader's |
+86 28 6587 8587 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
290475126@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
290475126@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
四川省成都市武侯区沙堰西二街290号 |
研究负责人通讯地址: |
成都市武侯区沙堰西二街290号 |
|
Applicant address: |
No.290, Shayan West Second Street, Wuhou District, Chengdu |
Study leader's address: |
No.290, Shayan West Second Street, Wuhou District, Chengdu |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
四川省妇幼保健院 |
||
|
Applicant's institution: |
Sichuan Provincial Women's and Children's Hospital |
||
|
研究负责人所在单位: |
四川省妇幼保健院 |
||
|
Affiliation of the Leader: |
Sichuan Provincial Maternity and Child Health Care Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
20260129-087 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
四川省妇幼保健院医学伦理审查委员会 |
||
|
Name of the ethic committee: |
The Medical Ethics Committee of Sichuan Provincial Maternity and Child Health Care Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2026-01-29 00:00:00 | ||
|
伦理委员会联系人: |
吴选玲 |
||
|
Contact Name of the ethic committee: |
Wu Xuanling |
||
|
伦理委员会联系地址: |
成都市武侯区沙堰西二街290号 |
||
|
Contact Address of the ethic committee: |
No.290, Shayan West Second Street, Wuhou District, Chengdu |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 28 65978298 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
494483182@qq.com |
|
研究实施负责(组长)单位: |
四川省妇幼保健院 |
||||||||||||||||||||||
|
Primary sponsor: |
Sichuan Provincial Maternity and Child Health Care Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
成都市武侯区沙堰西二街290号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No.290, Shayan West Second Street, Wuhou District, Chengdu |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
成都医学院联合科研基金 |
||||||||||||||||||||||
|
Source(s) of funding: |
Development and Regeneration Key Laboratory of Sichuan Province Fund Project |
||||||||||||||||||||||
|
研究疾病: |
妊娠期糖尿病 |
||||||||||||||||||||||
|
Target disease: |
gestational diabetes mellitus |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
析因分组(即根据危险因素或暴露因素分组) |
||||||||||||||||||||||
|
Study design: |
Factorial |
||||||||||||||||||||||
|
研究目的: |
通过16S rRNA基因扩增技术,比较妊娠期糖尿病孕妇与健康孕妇口腔、胎盘、阴道和肠道菌群的组成及结构特征差异(多样性、优势菌群、特有菌群等),阐明口腔、胎盘、阴道和肠道菌群的关联性、共变特征;通过相关网络分析,进一步探讨妊娠期糖尿病孕妇菌群与母婴血糖及炎性标志物的相关性,筛选与GDM 发生、血糖水平显著相关的多部位关键差异菌群,识别潜在微生态标志物,为GDM预警提供菌群依据,进而为GDM的管理提供新的方向。 |
||||||||||||||||||||||
|
Objectives of Study: |
Using 16S rRNA gene amplicon sequencing, we will compare the composition and structural characteristics (including diversity, dominant microbiota, and specific bacterial taxa) of the oral, placental, vaginal, and gut microbiota between pregnant women with gestational diabetes mellitus (GDM) and healthy controls. We aim to elucidate the inter-niche correlations and covariation patterns among these four body sites. Through correlation network analysis, we will further investigate the associations between maternal multi-site microbiota and maternal-fetal glycemic levels as well as inflammatory biomarkers. Ultimately, we seek to screen for key differential bacteria across multiple body sites that are significantly associated with GDM occurrence and glucose metabolism, identify potential microecological markers, and provide a microbial basis for early warning of GDM, thereby offering novel directions for GDM management. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1、孕前诊断为糖尿病; |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Pre-existing diabetes mellitus diagnosed prior to pregnancy; 2. Overt diabetes during pregnancy: Fasting plasma glucose ≥7.0 mmol/L, random plasma glucose ≥11.1 mmol/L, or HbA1c ≥6.5%; 3. Infectious or inflammatory conditions: Periodontitis, gingivitis, oral infections, acute gastroenteritis, inflammatory bowel disease, or other oral/gastrointestinal disorders within the past 3 months; 4. Medication interference: Use of antibiotics, probiotics, prebiotics, glucocorticoids, immunosuppressants, or other agents affecting microbiota within the past 1 month; 5. Comorbidities: Gestational hypertension, preeclampsia, thyroid disorders, autoimmune diseases, severe hepatic or renal dysfunction, malignant tumors, or other serious medical conditions; 6. Multiple or abnormal pregnancies: Multiple gestation, threatened abortion, fetal developmental abnormalities, or other conditions contraindicating study participation; 7. History of glucose metabolism disorders: Polycystic ovary syndrome (PCOS), Cushing's syndrome, or other conditions affecting blood glucose regulation; 8. Infectious diseases: Hepatitis B, Hepatitis C, HIV/AIDS, syphilis, or other communicable diseases; 9. Maternal lifestyle factors: Smoking or alcohol consumption during pregnancy; 10. Poor compliance or incomplete data: Inability to cooperate with sample collection/questionnaire completion, incomplete clinical documentation, or voluntary withdrawal from the study. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-01-01 00:00:00至 To 2028-12-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-05-10 00:00:00 至 To 2027-05-10 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
不共享 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
not shared |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病历记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |